Hepatitis C Information Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

Hep C information
Free Newsletter
Hepatitis C Newsletter
We value your privacy. We will not rent your email to anyone.
HEPATITIS NEWS
The top stories compiled from over 5,500 sources, updated every 15 minutes

Interferon as Long-Term Treatment for Hepatitis C Not Effective
Newswise Use of the drug interferon as a long-term maintenance strategy to slow the progression of liver disease associated with the hepatitis C virus is ineffective, researchers and their colleagues from nine other institutions have found in a

Delhi schoolkids made aware of hepatitis, organ donation
New Delhi (IANS): School children of Delhi were Thursday made aware of measures to combat dreaded liver disease, hepatitis, as well as the importance of organ donation in saving the lives of persons afflicted by it. Over 100 students attended the

Hepatitis C therapy useless for some
WEDNESDAY, Dec. 3 (HealthDay News) -- Maintenance therapy using low-dose peginterferon doesn't help patients with advanced chronic hepatitis C who haven't responded to an initial round of treatment, new research suggests. The study also showed a

UPDATES AND COMMENTARY RSS Feed

Hep C Study Reveals Taribavirin a Good Alternative to Ribavirin
At the end of a 48-week, Phase IIb study, taribavirin shows similar effectiveness as ribavirin in reducing Hepatitis C viral load. However, participants taking taribavirin had a significantly lower rate of anemia....

Schering-Plough Developing Potent Protease Inhibitor for Hepatitis C
An ongoing Phase IIa study on Schering-Plough's next generation Hepatitis C protease inhibitor is encouraging. According to the company, SCH 900518 is 10 times more potent than other medications in this class and is active against highly resistant Hepatitis C...

New Drug Finds Viral Hiding Spots
A new, experimental drug helps the immune system locate a virus by flagging cells that have turned inside out. Hepatitis C is among the viruses that could benefit from Bavituximab's unique strategy of exposing a virus in hiding....

Chronic Hepatitis B

Chronic carriers of the Hepatitis B virus have been defined as those who are Hepatitis B surface antigen positive for greater than 6 months.

These have generally been characterised as either healthy carriers who are anti-HBe positive with normal ALTs, or as patients with chronic Hepatitis B.

However it is clear that there is a variable course looking at clinical, biochemical and virological markers between these two case definitions.

Therefore it has been suggested that it may be more reasonable to classify chronically infected patients with Hepatitis B based on their serological and biochemical status.

† This would lead to three classifications, the first being patients who are e antigen positive with raised ALTs. These patients would also be Hepatitis B DNA positive and core antigen positive in the liver cells. These patients have ongoing active viral replication and evidence of liver damage due to Hepatitis B.

† A second classification would be patients who are e antigen negative, but have a raised ALT. These patients could be subdivided into two groups - one which has Hepatitis B DNA detectable as well as core antigen in liver.

Such patients may well be infected with the pre core mutant of Hepatitis B in which e antigen is not secreted but these patients do have detectable DNA suggesting that they have ongoing replication of this mutant Hepatitis B virus. There are other patients who are also e antigen negative, but have raised ALTs, but have no evidence of ongoing Hepatitis B replication in that they are DNA negative and have no core antigen in their liver.

It is important in this group to look for other causes of liver damage in a patient with chronic Hepatitis B surface antigenaemia.

Such patients may have ongoing liver damage due to superinfection with Hepatitis A, Hepatitis C or delta hepatitis.

They may also have liver damage due to other causes such as drugs or toxins such as alcohol.

† Finally the third group of patients are Hepatitis B e antigen negative, DNA negative, with no core antigen in their liver and normal ALTs.

These patients who are still surface antigen positive would fit the older definition of healthy carriers since they appear not to have any evidence of ongoing viral replication, nor is there evidence of other liver damage as characterised by raised ALT.

  Hep C information

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 05 Dec 2008